A look at the ‘war on drugs’
A new drug from a leading U.S. pharmaceutical company is drawing interest from some lawmakers in the face of mounting opposition.
Humana Pharmaceuticals says it is developing a drug to treat chronic fatigue syndrome.
The drug, called Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, or ME/CFS, is a condition in which people with chronic fatigue can feel sick.
It’s also known as chronic fatigue, or CFS.
ME/CNFS is often treated with drugs to help manage fatigue, but there’s been a lot of controversy surrounding its effectiveness.
Now, some lawmakers and advocates are calling for the FDA to allow the drug to be sold in the United States.
FDA officials have said they have no plans to change how the agency classifies drugs.
In a press release, Humana said its drug will target “an important emerging area of treatment” for people with CFS and “should be considered for FDA approval as soon as possible.”
Humana CEO Michael G. Jablonsky said the drug will work by targeting a “small but significant” subset of patients with CFA and should not require a new approval.
Humanas drug, known as Myalgico, was developed by a company called AbbVie.
The company, founded in 2005, is based in Indianapolis.
The drug has been approved in the U.K., where it was used in trials for depression and bipolar disorder, and the U, and was approved in 2012 in Europe.
Some of the critics to the FDA’s drug classifications say the FDA has failed to give enough consideration to other drug candidates for its approval.
“There’s been an extraordinary amount of controversy in this area,” said Sen. Chuck Grassley, R-Iowa, who heads the Senate Judiciary Committee.
“But I believe it’s important for the public to have a little bit more information before they vote on the merits of this drug.”
Sen. Chris Coons, D-Del., said that he is concerned the FDA will allow Myalgica to be used in Europe because of its efficacy and safety record.
I think this is the first step in the right direction,” Coons said.
A spokesperson for the senator said Coons and Grassley are looking into the issue.
Read more: What you need to know about the fight against ME/CTS: This is an issue that has been around for decades and it’s time we address the issues and move forward.
A federal agency must act.
If we don’t act, then millions of Americans will die and our economy will suffer.
It is time to make it clear to the pharmaceutical industry that this disease is not just a matter of ‘if,’ but a matter a matter ‘when.’
If Congress wants to take action, then the U of A needs to stop acting like it is a distant, isolated entity that is not relevant to our society and that should be ignored.
We can’t wait for the next round of trials.
Americans have been dying from ME/CE for decades, but the issue has only become more pressing with new research findings.
The disease affects between one in eight and one in five adults, and up to a third of those who get the disease develop CFS, according to the UIC School of Public Health.
In 2016, more than half of the estimated 1.2 million people who were diagnosed with CFI in the US were diagnosed before they reached the age of 40.